# Medtronic Hugo Surgical Robot Wins FDA Clearance and Completes First US Cases
For the first time in more than two decades, a major medtech company has brought a new robotic surgery platform to the US market — and it is already cutting.
In February 2026, surgeon Jihad Kaouk at Cleveland Clinic completed the first commercial surgical case in the United States using Medtronic"s Hugo robotic-assisted surgery system: a prostatectomy that sent the patient home the following day. The milestone capped a rapid push that began in December 2025, when the FDA cleared Hugo for minimally invasive urologic procedures, making Medtronic the first large-scale competitor to challenge Intuitive Surgical"s grip on soft-tissue robotic surgery in the US since the da Vinci system arrived more than twenty years ago.
The clearance covers prostatectomy, nephrectomy, and cystectomy — procedures that together account for roughly 230,000 surgeries per year in the United States, where about 80 percent of urologic abdominal operations are already performed with robotic assistance.
A Modular Challenger
What makes Hugo distinct from incumbent systems is its modular, mobile design. Rather than a fixed-tower architecture, Hugo uses four interchangeable robotic arms on mobile carts that can be repositioned across operating rooms and even shared between departments. The open-console design gives surgeons greater situational awareness and reduces physical strain during long procedures.
"This case exemplifies Cleveland Clinic"s mission to lead surgical innovation and expand access to minimally invasive surgery," said Dr. Kaouk after completing the first US case. "The new technology allows us to customize the approach for each patient case."
Hospitals have taken notice. Cleveland Clinic, Duke University Hospital, and Atrium Health Wake Forest Baptist High Point Medical Center were among the first US institutions to install the system, with Atrium Health being the first hospital outside the original clinical study to do so.
The AI Layer: Touch Surgery Ecosystem
Hugo is not just a robot — it is a data platform. The system connects to Medtronic"s Touch Surgery ecosystem, an AI-powered suite that provides pre-operative training tools, remote tele-proctoring, and post-operative case analytics. Surgeons can securely access case videos within seconds of completing a procedure, enabling continuous performance improvement.
This digital layer is where the long-term competitive moat may form. As more procedures are performed on Hugo, the data flywheel spins faster, feeding AI models that can surface insights on surgical technique, complication patterns, and efficiency benchmarks. In a market where Intuitive Surgical controls an estimated 70 percent of procedures through its da Vinci fleet, Medtronic"s AI-first ecosystem strategy represents a deliberate effort to compete not just on hardware but on intelligence.
"The future of surgery is not about robotics as a separate modality, it is about technology that enables surgical teams to deliver the best possible care for every patient," said Rajit Kamal, vice president and general manager of Robotic Surgical Technologies at Medtronic. "Medtronic is uniquely positioned to do that as the only company in the world that can partner with surgeons and hospitals across open, laparoscopic, and robotic-assisted surgery."
A Market in Motion
The surgical robotics market is valued at roughly $9 billion in 2026, according to Mordor Intelligence, with projections ranging from $38 billion to $46 billion by 2035 depending on the research firm. The sector is growing at a compound annual rate above 16 percent, fueled by aging populations, surgeon preference for minimally invasive techniques, and expanding indications beyond urology into gynecology, general surgery, and orthopedics.
The competitive field is intensifying. Intuitive Surgical remains dominant in soft tissue. Stryker"s Mako platform leads in orthopedic robotic surgery. CMR Surgical"s Versius system, like Hugo, uses a modular cart-based design. And Medtronic itself cleared a second robotic product — Stealth AXiS, for cranial navigation — in February 2026, signaling broader ambitions across the surgical portfolio.
Hospitals are increasingly drawn to modular systems that offer lower infrastructure footprints, faster setup, and greater scheduling flexibility compared to fixed-tower designs. Hugo"s mobile architecture directly addresses operating room capacity constraints that limit how many patients can access minimally invasive care.
What to Watch
Medtronic plans to expand Hugo"s US indications beyond urology into gynecologic and general surgery procedures, including hernia repair. Internationally, the system is already cleared in more than 35 countries and has been used in tens of thousands of procedures across urology, gynecology, and general surgery.
The Expand URO clinical trial — the largest ever completed for multi-port robotic-assisted urological surgery in the US — demonstrated that Hugo met primary safety and effectiveness endpoints, with outcomes consistent with published literature. That data package gives Medtronic a strong foundation for subsequent indication filings.
The real question is not whether Hugo can perform surgery safely. It already has. The question is whether Medtronic"s combination of modular hardware, AI-powered analytics, and cross-modality partnerships can erode the entrenched advantages of incumbents fast enough to reshape how hospitals think about surgical robotics. With the first US cases behind it and an aggressive expansion roadmap ahead, the answer may come sooner than the market expects.